Loading…
← CockpitCompetitor Analysis › 1112.HK Health and Happiness (H&H) International Holdings LimitedOpen in the cockpit ↗

Health and Happiness (H&H) International Holdings Limited1112.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Other

Consumer-health group selling infant formula/probiotics (Biostime), vitamins (Swisse) and pet nutrition (Solid Gold) globally.

≈ A Chinese/Australian Reckitt-style baby & wellness nutrition groupMomentum leader 98
Mkt cap
$2.15B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$9.03M
20-day average traded
Fwd P/E
13.2×
forward earnings
ROIC−WACC
+6.9 pp
WACC 9.6%
Hurdle
-6 pp
Req g minus delivered
Next earnings
125 days
23 Mar 2027
Close · HKDHK$26.32
1D-1.3%
1W+4.1%
1M+24.6%
3M+72.0%
6M+108.2%
YTD+100.6%
1Y+105.8%
ATR %4.1%
52w lowhigh1.9% off high

What Health and Happiness (H&H) International does

Consumer-health group selling infant formula/probiotics (Biostime), vitamins (Swisse) and pet nutrition (Solid Gold) globally.

Grew by buying brands: Swisse was bought in 2015, and Solid Gold and Zesty Paws added pet nutrition later. Swisse sells in Australia and China; China remains the largest market, much of it through online platforms, including cross-border channels.

In one line: A Chinese/Australian Reckitt-style baby & wellness nutrition group.

Products and services

  • Biostime infant formula/probiotics
  • Swisse vitamins/supplements
  • Solid Gold pet nutrition
  • Adult nutrition

Customers

  • Parents/infants in China
  • Health-conscious consumers globally
  • Pet owners

Where it sits in the supply chain

  • Consumer staples
  • Nutrition & wellness brands
  • Infant formula, vitamins, pet food

What could go right

  • China cross-border e-commerce nutrition demand
  • Pet nutrition growth

What could go wrong

  • China birth-rate decline hurting infant formula
  • Brand/regulatory scrutiny in China

Moat: narrow (brand, distribution). Strong Swisse/Biostime brand recognition and cross-border e-commerce distribution in China.

Headquarters: Guangzhou, China / Australia · Founded: 1999 · Employees: 2,758

Named competitors

Health and Happiness (H&H) International at a glance

Size Health and Happiness (H&H) International (1112.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $2.15B, the 392nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$26.32 on 18 Nov 2026.

Performance Over six months the shares gained 108.2%, against -3.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 24.3% over the last twelve months (peer median +8.3%); the operating margin is 15.6% (peer median 15.8%).

Valuation It trades at 13.2× forward earnings against a peer median of 17.0× (7th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.9 points above its cost of capital (9.6% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20261112.HK 211Peer median 96
Six months, rebased to 100: Health and Happiness (H&H) International against the median of its 20 peers (local-currency closes).

Health and Happiness (H&H) International financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$17.9BHK$15.6BHK$14.2BHK$15.4BHK$14.9B
Revenue growth—+10%-8%+4%—
Gross profitHK$11.5BHK$9.72BHK$8.58BHK$9.17BHK$8.96B
EBITDAHK$3.14BHK$2.15BHK$1.75BHK$2.15BHK$2.17B
Net incomeHK$833MHK$213M-HK$58.2MHK$643MHK$711M
Free cash flowHK$1.86BHK$1.05BHK$644MHK$342MHK$1.13B
Capital expenditureHK$103MHK$102MHK$106MHK$101MHK$119M
Total debtn/aHK$10.1BHK$9.96BHK$10.2BHK$10.9B

Quarterly statements and history in the cockpit →

Health and Happiness (H&H) International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%GRANULES600750600062600056300146300363002317600216SUDEEPPHRMBHCJWEL6472002603PHMCRON0022751112.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Health and Happiness (H&H) International is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×50×GRANULES600750600062300146002317600216SUDEEPPHRMBHCJWEL6472BIOG-B002603PHMCRON21421112.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Health and Happiness (H&H) International is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%GRANULES600750600062600056300146300363002317600216BHCJWEL6472PHMCRON21421112.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Health and Happiness (H&H) International is the large dot.

Health and Happiness (H&H) International competitors and peer comparison

Head to head with its named competitors (1112.HK vs RKT.L vs NESN.SW vs BN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Health and Happiness (H&H) International 1112.HK$2.15B+108%+24%16%13.2×-1.7%
Reckitt Benckiser RKT.L$47.5B+22%-2%28%16.7×2.1%
Nestle NESN.SW$258B+8%-2%16%19.1×1.3%
Danone BN.PA$48.7B+13%0%15%17.5×-0.2%

How Health and Happiness (H&H) International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Health and Happiness (H&H) International against its 20 peers (data as of 18 Nov 2026)
Measure1112.HKPeer medianRank in peer set
1-month return+24.6%-1.3%2nd highest of 21
6-month return+108.2%-3.5%highest of 21
Distance from 52-week high-1.9%-26.3%3rd highest of 21
Revenue growth (TTM)+24.3%+8.3%6th highest of 21
Operating margin15.6%15.8%11th highest of 21
Forward P/E13.2×17.0×7th cheapest of 17
Growth the price implies (Req g, 7 yrs)-1.7%2.1%8th least demanding of 20
Growth delivered (Del g)+4.4%+5.9%7th lowest of 20
Hurdle (Req g minus delivered)-6.0 pp-8.3 pp9th most demanding of 20
ROIC minus cost of capital+6.9 pp+2.7 pp8th highest of 21
EV / EBITDA7.5×17.3×2nd cheapest of 10
Net debt / EBITDA2.1×-0.3×4th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%

Questions

Who are Health and Happiness (H&H) International's main competitors?
Named competitors: Reckitt Benckiser (RKT.L), Nestle (NESN.SW), Bubs Australia (private or unlisted), Danone (BN.PA). The cockpit's measured peer set (industry) also includes Granules India (GRANULES.NS), China Resources Jiangzhong Pharmaceutical (600750.SS), China Resources Double-Crane Pharmaceutical (600062.SS), China Meheco (600056.SS), By-health (300146.SZ), Porton Pharma Solutions (300363.SZ).
Is Health and Happiness (H&H) International expensive compared with its peers?
On forward p/e it trades at 13.2× against a peer median of 17.0×, 7th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has Health and Happiness (H&H) International stock performed?
Over six months to 18 Nov 2026 the shares returned +108.2% against -3.5% for the median peer; over one year +105.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.